196 results
Page 7 of 10
8-K
EX-3.1
um7jhp1qx
20 Jun 19
ContraVir Pharmaceuticals, Inc. Announces Pricing of $15.6 Million Public Offering
4:30pm
424B4
d1tpnvp9b927fupc
19 Jun 19
Prospectus supplement with pricing info
5:25pm
8-K
EX-99.1
sr8 t9gto6122
17 Jun 19
Compelling Positive Results Reported from Human Liver Experiments with ContraVir Pharmaceuticals’ NASH Drug Candidate
11:18am
8-K
EX-99.1
ub22nvhl
11 Jun 19
ContraVir Pharmaceuticals Announces Publication of CRV431 Data from
12:33pm
8-K
EX-99.1
e68m7xgm
6 Jun 19
ContraVir Pharmaceuticals Sets the Stage for CRV431 Development in NASH with Positive Results from Second Model of Liver Fibrosis
11:28am
8-K
EX-99.1
otgjl vfqe1
31 May 19
ContraVir Pharmaceuticals, Inc. Announces Reverse Stock Split
8:30am
8-K
EX-3.1
xa7y6mtozifq2
8 May 19
Amendments to Articles of Incorporation or Bylaws
4:34pm
8-K
EX-99.1
hinbd47moph 2n
6 May 19
ContraVir Pharmaceuticals Receives Positive Nasdaq Listing Decision
12:55pm
424B4
3lfrb3c dufxhnezn
26 Apr 19
Prospectus supplement with pricing info
3:56pm
8-K
EX-10.1
oc8o2r obizbq7ton
19 Mar 19
Entry into a Material Definitive Agreement
4:56pm